🔔 NEWS: Today, we shared new data from our ARC-20 platform study that further demonstrated the potential of the investigational molecule casdatifan, alone or in combination as a first-, second- and late-line treatment for #KidneyCancer. Data exceeded benchmarks for existing standards of care and validated our intention to develop casdatifan so that every patient may have the opportunity to benefit from it across each line of therapy over the course of their care. Read more: bit.ly/4jwvlda “Across the RCC treatment continuum, and in every setting in which it has been studied, casdatifan has shown rapid disease control, a meaningful impact on survival, and was tolerable, both alone and in combination with standard-of-care therapies. These are the attributes that matter most to physicians and patients.” Rana McKay, M.D. Professor of Medicine, Urology, and Radiation Medicine Associate Director of Clinical Sciences UC San Diego Moores Cancer Center

🔔 Save the date for our investor event in NYC, where Arcus leadership will be presenting an update on casdatifan, our investigational HIF-2α inhibitor for #KidneyCancer, including new data from our ARC-20 platform study of casdatifan alone and in combination across first-line, second-line, and late-line treatment. We'll also share our strategy to establish casdatifan as a backbone therapy, so every patient has the opportunity to benefit across each line of their care. Learn more: bit.ly/4y8xbW9

We’re reporting our second-quarter financial results and an update on our clinical-stage pipeline: bit.ly/4fVFqNp "The ARC-20 platform study and strategic clinical collaborations are enabling us to efficiently pursue an integrated approach across multiple lines of therapy, and we expect this year’s upcoming ARC-20 data readouts in first-, second- and late-line settings to clarify casdatifan’s potential to transform the treatment paradigm for kidney cancer." - Terry Rosen, Ph.D. Chief Executive Officer Arcus Biosciences

🔔 NEWS: We are pleased to announce a clinical supply agreement with @AVEOOncology to evaluate casdatifan, our investigational HIF-2α inhibitor, in combination with a VEGFR tyrosine kinase inhibitor, in a new cohort of our ARC-20 platform study for patients with advanced #KidneyCancer who have received prior treatment with a HIF-2α inhibitor. Learn more about this collaboration: bit.ly/4wYcmLX “This collaboration with AVEO, combining casdatifan with tivozanib, a VEGFR TKI, will further our intent to establish casdatifan as a potential therapy that can benefit every patient across each line of therapy.” Terry Rosen, Ph.D. Chief Executive Officer Arcus Biosciences

🔔 NEWS: Today we announced a clinical trial collaboration with @SMMT_TX to evaluate casdatifan, our investigational HIF-2α inhibitor, in combination with their investigational PD-1/VEGF bispecific antibody, in a new cohort of our ARC-20 platform study for patients with previously untreated advanced #KidneyCancer. Learn more about this collaboration: bit.ly/3TuFHz5 “Combining casdatifan, a HIF-2α inhibitor, with ivonescimab, the most clinically advanced and well-studied anti-PD-1/VEGF bispecific, presents a compelling opportunity to create a well-tolerated and TKI-sparing combination that has the potential to impact survival.” Terry Rosen, Ph.D. Chief Executive Officer Arcus Biosciences

Hear from our scientists and get a behind-the-scenes look on the first study to comprehensively investigate the connection between tumor biology, a signal in the blood and clinical outcomes in patients receiving a HIF-2α inhibitor. Learn more 🔗 bit.ly/4y1gufA

Honored to see our science lit up on the @NYSE trading floor today, congratulating our team on the recent @Nature publication featuring ARC-20 trial data. Grateful for the recognition! Learn more about the research here: bit.ly/4gS5jzv

Data from our ARC-20 platform study are now published in @Nature. Our #KidneyCancer study is the first to comprehensively explore the connection between tumor biology, a biomarker, and clinical activity for a HIF-2α inhibitor. Learn more: bit.ly/4v3GrIv “The comprehensive translational work published in Nature validates EPO as a biomarker for HIF-2a suppression and correlates dramatic and sustained EPO suppression to durable response with monotherapy casdatifan.” Richard Markus M.D. Ph.D. Chief Medical Officer Arcus Biosciences

🔔 NEWS: We announced a clinical trial collaboration and supply agreement with @BMSnews to evaluate casdatifan, our investigational HIF-2a inhibitor, in combination with a PD-L1/VEGF-A bispecific immunomodulator in the Phase 1/2 ROSETTA RCC-208 trial in advanced #KidneyCancer. Read more: bit.ly/4x5w1KD “HIF-2a inhibition, PD-L1 and VEGF-A blockade are validated mechanisms in the treatment of kidney cancer with a strong biologic rationale for combination. This strategic collaboration with BMS is a top priority for Arcus in order to potentially deliver an additional effective TKI-free option in the first-line setting.” -Terry Rosen, Ph.D. Chief Exective Officer Arcus Biosciences

We’re reporting our first-quarter financial results and an update on our clinical-stage pipeline: bit.ly/4wbsv0R

We published safety, biomarker, and clinical outcome data in @NatureMedicine from the Phase 1b study of our investigational CD73 inhibitor. This research underscores a potential novel approach to treating metastatic #PancreaticCancer for which new treatment options are critically needed. Explore the research: bit.ly/3PJjSdl +++ “Investigating new approaches like CD73 inhibition with a small molecule is a critical step in exploring how targeting adenosine, a key driver of immune suppression, might ultimately make a meaningful impact on patient care. For people with pancreatic cancer, the unmet need for new treatment options is profound. These findings support CD73 as a therapeutic target in pancreatic cancer and we look forward to seeing the results of the Phase 3 PRISM-1 study in early 2027.” Zev A. Wainberg, M.D., MSc Co-Director of the GI Oncology Program at University of California Los Angeles and a principal investigator of the ARC-8 trial.

We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline: bit.ly/3MPV9D5

🔔 NEWS: Today we announced an update on our Phase 3 STAR-221 study evaluating domvanalimab plus zimberelimab and chemotherapy. Read more about this news and our future R&D focus: bit.ly/3MTYHng

We’re reporting our third-quarter financial results and an update on our clinical-stage pipeline. bit.ly/4p1JnDd

We are pleased to announce the fifth option exercise by Taiho to an Arcus program for an exclusive license to our investigational HIF-2a inhibitor for the treatment of #KidneyCancer, in Japan and certain territories in Asia. Read about this collaboration: bit.ly/43u7Bxg